Association of Biologic Therapy with Coronary Inflammation in Patients with Psoriasis as assessed by Perivascular Fat Attenuation Index
Chronic inflammatory diseases, including psoriasis, are associated with increased cardiovascular (CV) risk, which may be reduced when treating the underlying psoriasis.
This finding has opened interest to whether treating areas of low-grade inflammation in the body may be associated with downstream CV risk. A study of patients with moderate to severe psoriasis recently found that treatment of psoriasis with biologic therapy, including anti–tumor necrosis factor α (TNF-α), anti–interleukin (IL) 17, or anti–IL-12/23 therapy, may modulate coronary plaque compared with no biologic therapy.
Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy
In these contemporary data from 31 245 patients who are receiving statin therapy, residual inflammatory risk appears to be more…
Pericoronary Adipose Tissue as a Marker of Cardiovascular Risk
JACC Review Topic of the Week. In this review the authors aim to summarize the role of PCAT in cardiac…